| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
About sorafenib in castration-resistant prostate cancer
|
Colloca, G.
|
|
|
19 |
10 |
p. 1812-1813
|
article
|
| 2 |
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer
|
Sculier, J.P.
|
|
|
19 |
10 |
p. 1691-1697
|
article
|
| 3 |
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
|
von Mehren, M.
|
|
|
19 |
10 |
p. 1802-1809
|
article
|
| 4 |
A prospective study of pulmonary function in Hodgkin’s lymphoma patients
|
Ng, A.K.
|
|
|
19 |
10 |
p. 1754-1758
|
article
|
| 5 |
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
|
Sieniawski, M.
|
|
|
19 |
10 |
p. 1795-1801
|
article
|
| 6 |
Bevacizumab in advanced cancer, too much or too little?
|
Jirillo, A.
|
|
|
19 |
10 |
p. 1817-1818
|
article
|
| 7 |
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
|
Ménard, S.
|
|
|
19 |
10 |
p. 1706-1712
|
article
|
| 8 |
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma
|
Mendler, J.H.
|
|
|
19 |
10 |
p. 1759-1764
|
article
|
| 9 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
|
Rothenberg, M.L.
|
|
|
19 |
10 |
p. 1720-1726
|
article
|
| 10 |
Chemotherapy for breast cancer during pregnancy: is epirubicin safe?
|
Mir, O.
|
|
|
19 |
10 |
p. 1814-1815
|
article
|
| 11 |
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
|
Elstrom, R.L.
|
|
|
19 |
10 |
p. 1770-1773
|
article
|
| 12 |
Diet, nutrition and cancer: public, media and scientific confusion
|
Boyle, P.
|
|
|
19 |
10 |
p. 1665-1667
|
article
|
| 13 |
Editorial Board
|
|
|
|
19 |
10 |
p. ii-iii
|
article
|
| 14 |
HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007)
|
Termine, N.
|
|
|
19 |
10 |
p. 1681-1690
|
article
|
| 15 |
Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations
|
Cristofanilli, M.
|
|
|
19 |
10 |
p. 1713-1719
|
article
|
| 16 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
|
Salama, J.K.
|
|
|
19 |
10 |
p. 1787-1794
|
article
|
| 17 |
In this issue
|
|
|
|
19 |
10 |
p. 1663
|
article
|
| 18 |
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
|
Lafaras, C.
|
|
|
19 |
10 |
p. 1765-1769
|
article
|
| 19 |
Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study
|
Rom, J.
|
|
|
19 |
10 |
p. 1698-1705
|
article
|
| 20 |
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
|
Halfdanarson, T.R.
|
|
|
19 |
10 |
p. 1727-1733
|
article
|
| 21 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies
|
Tan, B.R.
|
|
|
19 |
10 |
p. 1742-1748
|
article
|
| 22 |
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
|
Lurje, G.
|
|
|
19 |
10 |
p. 1734-1741
|
article
|
| 23 |
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer
|
Hickey, M.
|
|
|
19 |
10 |
p. 1669-1680
|
article
|
| 24 |
Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas
|
Amara, K.
|
|
|
19 |
10 |
p. 1774-1786
|
article
|
| 25 |
Reply to the letter “About sorafenib in castration-resistant prostate cancer” by G. Colloca, F. Checcaglini and A. Venturino
|
Chi, K.N.
|
|
|
19 |
10 |
p. 1813-1814
|
article
|
| 26 |
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
|
Berthold, D.R.
|
|
|
19 |
10 |
p. 1749-1753
|
article
|
| 27 |
Table of Contents
|
|
|
|
19 |
10 |
p. iv-v
|
article
|
| 28 |
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study
|
Cazzaniga, M.E.
|
|
|
19 |
10 |
p. 1811-1812
|
article
|
| 29 |
Trastuzumab in inflammatory breast cancer
|
Mehta, R.S.
|
|
|
19 |
10 |
p. 1815-1817
|
article
|
Journal description